Ipamorelin Peptide Description

Ipamorelin peptide is a selective synthetic pentapeptide that functions as a growth hormone secretagogue (GHS) in laboratory studies. This research-grade compound binds specifically to ghrelin receptors without affecting cortisol, prolactin, or ACTH levels—a selectivity profile that distinguishes it from other growth hormone releasing peptides.

Manufactured in USA facilities under pharmaceutical-grade standards, each batch undergoes independent third-party testing to verify minimum purity. The white lyophilized powder maintains stability when stored at -20°C and reconstitutes readily in bacteriostatic water.

Peptide Specifications

SPECIFICATION	DESCRIPTION
Sequence	Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Formula	C38H49N9O5
Molecular Weight	711.85 g/mol
CAS Number	170851-70-4
PubChem CID	9831659
Synonyms	NNC-26-0161, Growth hormone releasing peptide
Purity	≥99% (HPLC)
Solubility	Soluble in water and DMSO
Storage Conditions	Store at -20°C, tightly sealed, away from heat and moisture
Physical Appearance	White to off-white lyophilized powder
Shelf Life	24-36 months from date of manufacture when stored properly
Quality Verification	Third-party tested by certified laboratory
Manufacturing Standard	USA-made, pharmaceutical-grade, GMP compliant
Intended Application	In vitro research applications only

Our Product Quality Guarantee

Every Limitless Biotech compound undergoes independent testing for endotoxins and sterility, meeting rigorous research standards through our systematic quality protocols and proactive manufacturing processes.

Buy Ipamorelin From Limitless Biotech

Limitless Biotech provides USA-manufactured Ipamorelin with verified molecular sequences and purity through comprehensive third-party testing. We ensure research quality with same-day shipping and dedicated customer support for your scientific endeavors.

Legal Disclaimer

This product is sold as a pure compound for research purposes only and is not meant for use as a dietary supplement. Please refer to our terms and conditions prior to purchase.

Safety Information: Keep this product out of the reach of children. This material has limited research available about it and may result in adverse effects if improperly handled or consumed. This product is not a dietary supplement, but a pure substance, sold as a raw material. We attest exclusively to the quality, purity and description of the materials we provide. This product is for use and handling only by persons with the knowledge and equipment to safely handle this material. You agree to indemnify us for any adverse effects that may arise from improper handling and/or consumption of this product.

The articles and information on products that may be found on this website are provided exclusively for the purposes of providing information and education. These items are not pharmaceuticals or medications, and the Food and Drug Administration has not given permission for the treatment or prevention of any disease, medical condition, or ailment using them.

Research

Ipamorelin is a synthetic peptide classified as a growth hormone secretagogue, designed to selectively stimulate the release of growth hormone (GH) by mimicking the action of ghrelin.

It has attracted research interest for its potential applications in growth, metabolism, gastrointestinal function, and tissue regeneration.

Growth Hormone Secretion and Selectivity

Ipamorelin is a selective growth hormone secretagogue (GHS) that stimulates release of growth hormone via the growth hormone secretagogue receptor, mimicking ghrelin’s action^[1][2].

It demonstrates high potency and efficacy in vitro and in vivo, comparable to GHRP-6, but with a unique selectivity: unlike other GHSs, ipamorelin does not significantly increase ACTH or cortisol levels, even at high doses^[3].

This specificity for GH release, without affecting other pituitary hormones, distinguishes ipamorelin from other growth hormone releasing peptides in research applications.

Effects on Body Weight, Adiposity, and Metabolism

Ipamorelin increases body weight and fat mass in animal models, with some effects independent of GH. In both GH-deficient and GH-intact mice, ipamorelin led to modest weight gain and increased fat pad weights, likely through increased food intake and elevated serum leptin^[4].

In steroid-treated rats, ipamorelin counteracted nitrogen wasting and improved nitrogen balance, though less efficiently than GH itself^[5].

Bone Density and Tissue Regeneration

Chronic administration of ipamorelin in rats dose-dependently increased longitudinal bone growth rate and body weight, without altering IGF-I levels or bone turnover markers^[6][7].

The treatment did not significantly affect bone resorption or formation markers, suggesting the primary effect is on growth rate rather than bone remodeling.

Gastrointestinal Motility and Postoperative Ileus

Ipamorelin accelerates gastric emptying and improves gastrointestinal transit in rodent models of postoperative ileus. Repetitive dosing increased fecal output, food intake, and body weight gain post-surgery^[8][9].

These findings demonstrate promotility effects in preclinical models across multiple gastrointestinal parameters.

Reproductive and Endocrine Effects

In fish models, ipamorelin increased food intake and enhanced spermatogenesis, with elevated androgen receptor expression and higher serum LH and 11-ketotestosterone levels^[10].

In rats, ipamorelin stimulated insulin release from pancreatic tissue via calcium channel and adrenergic pathways, in both normal and diabetic states^[11].

These results indicate broader endocrine effects beyond GH release in various animal model systems.

Referenced Sources

Raun, K., Hansen, B., Johansen, N., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. Ipamorelin, the first selective growth hormone secretagogue.. European journal of endocrinology. 1998; 139 5. https://doi.org/10.1530/EJE.0.1390552
Ipamorelin. Definitions. 2020 https://doi.org/10.32388/22pzq4
Ankersen, M., Johansen, N., Madsen, K., Hansen, B., Raun, K., Nielsen, K., Thøgersen, H., Hansen, T., Peschke, B., Lau, J., Lundt, B., & Andersen, P. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.. Journal of medicinal chemistry. 1998; 41 19. https://doi.org/10.1021/JM9801962
Lall, S., Tung, L., Ohlsson, C., Jansson, J., & Dickson, S. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues.. Biochemical and biophysical research communications. 2001; 280 1. https://doi.org/10.1006/BBRC.2000.4065
Aagaard, N., Grøfte, T., Greisen, J., Malmlöf, K., Johansen, P., Grønbaek, H., Ørskov, H., Tygstrup, N., & Vilstrup, H. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009; 19 5. https://doi.org/10.1016/j.ghir.2009.01.001
Johansen, P., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T., Wilken, M., & Orskov, H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999; 9 2. https://doi.org/10.1054/GHIR.1999.9998
Papak, M. Ipamorelin – struktura i funkcija. . 2016
Venkova, K., Mann, W., Nelson, R., & Meerveld, B. Efficacy of Ipamorelin, a Novel Ghrelin Mimetic, in a Rodent Model of Postoperative Ileus. Journal of Pharmacology and Experimental Therapeutics. 2009; 329. https://doi.org/10.1124/jpet.108.149211
Meerveld, G., Tyler, K., Mohammadi, E., & Pietra, C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology. 2012; 4. https://doi.org/10.2147/JEP.S35396
Gouda, M., & Ganesh, C. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus.. Animal reproduction science. 2024; 268. https://doi.org/10.1016/j.anireprosci.2024.107550
Adeghate, E., & Ponery, A. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats.. Neuro endocrinology letters. 2004; 25 6.